Parkinsonian Patients Requiring Proteasome Inhibitors for Multiple Myeloma: Exceptional Circumstances Call for Extra Caution

J Parkinsons Dis. 2022;12(8):2601-2603. doi: 10.3233/JPD-223496.

Authors

Pierre Rocanières¹, Sylvain Lamure², Christian Geny³, Dominique Hillaire-Buys¹, Jean-Luc Faillie^{1

4}, Virginie Bres¹

Affiliations

¹ Department of Medical Pharmacology and Toxicology, Pharmacovigilance Regional Centre, CHU Montpellier, Montpellier, France.
² Department of Clinical Hematology, CHU Montpellier, IGMM UMR5535 CNRS, Univ Montpellier, Montpellier, France.
³ Department of Internal Medicine and Geriatrics, CHU Montpellier, Montpellier, France.
⁴ Desbrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM, Montpellier, France.

PMID: 36189606
DOI: 10.3233/JPD-223496

No abstract available

Publication types

Letter

MeSH terms

Cell Line, Tumor
Humans
Multiple Myeloma* / complications
Multiple Myeloma* / drug therapy
Parkinson Disease*
Proteasome Endopeptidase Complex
Proteasome Inhibitors / pharmacology
Proteasome Inhibitors / therapeutic use

Substances

Proteasome Inhibitors
Proteasome Endopeptidase Complex